Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cass

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Crisis|November 22, 2016
An Intervention With MeaningBrooke A Levandowski, Constance M Cass, Stephanie N Miller, et al.
Cancer Research|January 1, 1983
Effect of methylazoxymethanol acetate on rat liver nuclear and nucleolar RNA synthesisF L Yu, G Hunter, M Cass, et al.
The Laryngoscope|September 9, 2018
Demographic predictors of head and neck cancer survival differ in the elderlySean T Massa, Lauren M Cass, Sai Challapalli, et al.
Clinical Pharmacokinetics|August 3, 1999
Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteersL M Cass, J Brown, M Pickford, et al.
The Laryngoscope|November 15, 2021
Radiation-Associated Sarcoma of the Head and Neck: Incidence, Latency, and SurvivalJoshua B Smith, Lauren M Cass, Matthew C Simpson, et al.
European Journal of Clinical Pharmacology|April 11, 2001
Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitorK H Moore, L M Cass, N Dallow, et al.
Head & Neck|June 23, 2017
Decreased cancer-independent life expectancy in the head and neck cancer populationSean T Massa, Lauren M Cass, Nosayaba Osazuwa-Peters, et al.
Clinical Pharmacokinetics|August 3, 1999
Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomographyM Bergstrom, L M Cass, S Valind, et al.
Journal of Clinical Pharmacology|May 22, 2001
The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteersL M Cass, K H Moore, N S Dallow, et al.
Journal of Clinical Pharmacology|October 5, 2001
Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteersK H Moore, L M Cass, N Dallow, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Crisis|November 22, 2016
An Intervention With MeaningBrooke A Levandowski, Constance M Cass, Stephanie N Miller, et al.
Cancer Research|January 1, 1983
Effect of methylazoxymethanol acetate on rat liver nuclear and nucleolar RNA synthesisF L Yu, G Hunter, M Cass, et al.
The Laryngoscope|September 9, 2018
Demographic predictors of head and neck cancer survival differ in the elderlySean T Massa, Lauren M Cass, Sai Challapalli, et al.
Clinical Pharmacokinetics|August 3, 1999
Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteersL M Cass, J Brown, M Pickford, et al.
The Laryngoscope|November 15, 2021
Radiation-Associated Sarcoma of the Head and Neck: Incidence, Latency, and SurvivalJoshua B Smith, Lauren M Cass, Matthew C Simpson, et al.
European Journal of Clinical Pharmacology|April 11, 2001
Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitorK H Moore, L M Cass, N Dallow, et al.
Head & Neck|June 23, 2017
Decreased cancer-independent life expectancy in the head and neck cancer populationSean T Massa, Lauren M Cass, Nosayaba Osazuwa-Peters, et al.
Clinical Pharmacokinetics|August 3, 1999
Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomographyM Bergstrom, L M Cass, S Valind, et al.
Journal of Clinical Pharmacology|May 22, 2001
The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteersL M Cass, K H Moore, N S Dallow, et al.
Journal of Clinical Pharmacology|October 5, 2001
Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteersK H Moore, L M Cass, N Dallow, et al.
Pageof 6